Contact For Feasibility
Neeman & Industry News
DCGI to implement e-Gov in its working The Drugs Controller General of India (DCGI) to have a single window facility for drug approval soon...
New Indian Regulatory Guidance by Central Drugs Standard Control Organization Guidance for Industry on Submission of Clinical Trial Application for Evaluating Safety and Efficacy - Central Drugs Standard Control Organization...
Indian Clinical Data Management market is expected to ramp up to $150 million MNCs are more than willing to outsource their needs to India because of it\'s technological innovation, creditable quality, operational flexibility, cost effectiveness, time-to-market and competitive advantage according to Koteshwar Govind, Deputy Manager,...
India: Attractive Market for Biopharmaceutical Companies Looking to Accelerate Their Clinical Trials The Clinical Research Market in India is growing at a very rapid rate according to anyone’s statistics…It is exploding according to all the hype. ...

Contact For Feasibility


Presence in 5 metros and 22 cities with 106 study centres all across India, Max Neeman International can produce efficiencies by ensuring you maximize your recruitment rate and quality data.

Pan–India presence enables us to access larger pools of patients with variety of diseases at each site than can be found in most European countries and the US.

If your development program is behind schedule due to slow patient recruitment. Contact us for Feasibility: bd@neemanasia.com